SCHEMBL6160795

SCHEMBL6160795

CC(C)(C)OC(=O)NC1(C(=O)N[C@H](COCc2ccccc2)C(=O)N2CCC(n3c(=O)[nH]c4ccccc43)CC2)CC1

nearest known ligand 0.51

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
CALCRL Q16602 15/20 0.51
CYP3A4 P08684 8/20 0.49
CCR5 P51681 1/20 0.46
RAMP1 O60894 1/20 0.45
HSD11B1 P28845 1/20 0.44
CHRM2 P08172 1/20 0.43
CHRM4 P08173 1/20 0.43
CHRM5 P08912 1/20 0.43
CHRM1 P11229 1/20 0.43
CHRM3 P20309 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6160802 1.00 CALCRL (0.51) CALCRLCYP3A4CCR5RAMP1HSD11B1
SCHEMBL6162765 0.97 CALCRL (0.51) CALCRLCYP3A4CCR5RAMP1HSD11B1
SCHEMBL6162769 0.97 CALCRL (0.51) CALCRLCYP3A4CCR5RAMP1HSD11B1
SCHEMBL6161677 0.90 CALCRL (0.57) CALCRLCYP3A4CCR5RAMP1HSD11B1
SCHEMBL6162040 0.86 CALCRL (0.52) CALCRLCYP3A4CCR5RAMP1HSD11B1
SCHEMBL6162035 0.86 CALCRL (0.52) CALCRLCYP3A4CCR5RAMP1HSD11B1
SCHEMBL6163808 0.85 CALCRL (0.51) CALCRLCYP3A4CCR5RAMP1HSD11B1
SCHEMBL6163802 0.85 CALCRL (0.51) CALCRLCYP3A4CCR5RAMP1HSD11B1
SCHEMBL6163603 0.83 CALCRL (0.59) CALCRLCYP3A4RAMP1HSD11B1
SCHEMBL6161636 0.83 CALCRL (0.59) CALCRLCYP3A4RAMP1HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0939632-B1 NON-PEPTIDYL VASOPRESSIN V1a ANTAGONISTS LILLY CO ELI (US) 2005-10-05 EP disclosed
EP-0828754-B1 DIPEPTIDES WHICH PROMOTE RELEASE OF GROWTH HORMONE PFIZER (US) 2005-02-02 EP disclosed
US-6610680-B1 Administering as adjuncts in heart failure or as antithrombotic agents, treatment of obsessive-compulsive disorder, aggressive disorders, depression and anxiety ELI LILLY AND COMPANY 2003-08-26 US disclosed
US-20020049187-A1 Non-peptidyl vasopressin V1a antagonists BRUNS ROBERT F (US) 2002-04-25 US disclosed
US-6204260-B1 2-(AZETIDIN-2-ON-1-YL)ACETIC ACID DERIVATIVES ELI LILLY AND COMPANY 2001-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049187-A1 Non-peptidyl vasopressin V1a antagonists AVPR1A, AVPR2, AVPR1B CALCRL 124/4885CYP3A4 4049/4885CCR5 691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.